Document is current
Any future updates will be listed below
-
Authors
Smith, Jill P.
Mohit, Mahdis
Kenner, Joi
Nathan, Ajay
Drda, Jack
Gay, Martha D.
Cao, Hong
Chen, Wenqiang
Gomeiz, Alison
Baldelli, Elisa
Dou, Wenyu
Fang, Hong-Bin
Shivapurkar, Narayan
Davis, James
Wei, Qi
Akhrif, Abdellah
Pierobon, Mariaelena
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA277680)
National Cancer Institute (P30-CA051008)
American Cancer Society (DICR INTR-23)
American Physiological Society (No number)
- License Information
-
More Information
Article History
Received: 1 August 2025
Accepted: 11 January 2026
First Online: 16 January 2026
Declarations
:
: Competing Interests: Georgetown University owns an issued patent for the use of proglumide in pancreatic cancer and Dr Jill Smith is a co-inventor; Mariaelena Pierobon is an inventor of university-assigned patents and patent applications and received royalties from and consulted for TheraLink Technologies. The other authors have no competing interests.
